Corporate Finance
Merck joins in on the acquisition spree in the healthcare industry: Prometheus Biosciences for $10.8bn
Download PDF Introduction This week Merck & Co. announced one of the biggest healthcare deals disclosed so far in 2023. The US drug maker reached an agreement with Prometheus Biosciences to acquire the company in an all-cash transaction that values Prometheus at $10.8bn, a 75% premium to its market cap Read more…